ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MGNX vs DERM // EV/EBITDA & P/E VALUATION

MacroGenics Inc. (NASDAQ) VS. Journey Medical Corporation (NASDAQ) • 15-METRIC TALLY: MGNX 2 — DERM 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MGNX VS. DERM) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MGNX DERM SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 96.00% 65.80% +30.20 MGNX /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -19.50% -15.50 DERM /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — -8.15% — TIE /fcf-yield <GO>
Operating Margin -48.70% -13.30% -35.40 DERM /operating-margins <GO>
Net Profit Margin 0.00% -18.70% +18.70 MGNX /net-margins <GO>
Revenue Growth (YoY) -0.30% 11.10% -11.40 DERM /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.74 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 5/9 -3.00 DERM /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 33.0 40.5 -7.47 DERM /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $151.6M $152.7M -$1.1M DERM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MGNX REV DERM REV MGNX GROSS % DERM GROSS % MGNX FCF DERM FCF
FY 2025 $149.5M $61.2M 98.0% 65.8% -$83.0M -$12.4M
FY 2024 $150.0M $55.1M 98.0% 62.1% -$72.1M -$9.1M
FY 2023 $58.7M $59.7M — — -$78.2M $5.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MGNX // BETA —
DERM // BETA —